Wednesday, 4 May 2016
Anyone still taking Rintega?
My wife had a subtotal resection of a GBM tumor on 3/29. She started TMZ and radiation on Monday but I want to take a more proactive approach as opposed the current reactive SOC approach -- with that said - her tumor shows amplification of the EGFR biomarker. As we know Rintega (Rindopepimut) vaccine had some good success with EGFR patient but didn't make the cut on the PhaseIII trial. But Rintega HAS worked for some in the past - http://bit.ly/1UzcqMS. My thinking? -- why can't my wife be one of those winners like those who have used Rintega? So -- my question is - is anyone still taking and have access to this drug? Thanks.
Subscribe to:
Post Comments (Atom)
SoDoWarts, Rintega targets a variant of EGFR called EGFRvIII. It can but doesn't always develop in those with EGFR amplifications. There is a promising drug for targeting EGFR amplifications:
ReplyDeletehttps://clinicaltrials.gov/ct2/results?term=ABT-414&recr=Open
Data:
http://adcreview.com/editorial/randomized-phase-ii-trial-abt-414-patients-glioblastoma-multiforme/
Were there any other markers that showed up with the genetic testing?
ReplyDeleteDavid- I just received the report for the vIII mutation and it is positive. What other biomarkers are you curious about? Thank you!
DeleteI'm just curious if the oncologist ran a broader panel and what turned up. Most alteration in glioma are just informative unless something unusual turned up. It is a good sign that they tested EGFR and EGFRvIII.
DeleteThe trial above uses an effective drug, it is randomized and open-label so you know what drug you receive. If you get allocated to standard of care, withdrawel is possible.
Here are some that target EGFR/EGFRvIII:
https://clinicaltrials.gov/ct2/show/NCT02209376
https://clinicaltrials.gov/ct2/show/NCT02303678
https://clinicaltrials.gov/ct2/show/NCT01967758
https://clinicaltrials.gov/ct2/show/NCT02378532
https://clinicaltrials.gov/ct2/show/NCT02432417
https://clinicaltrials.gov/ct2/show/NCT02754362
Some of these could be options now:
https://clinicaltrials.gov/ct2/results?term=newly+diagnosed+vaccine+glioma&recr=Open
https://clinicaltrials.gov/ct2/results?term=newly+diagnosed+glioblastoma&recr=Open
In addition to trials there are two other options:
1. Vaccines treatments are available from facilities in Europe, I think they can target EGFRvIII. They can be quite expensive, the best places would be http://www.immune-therapy.net/
http://www.unifontis.net/en/
There are studies using chloroquine. It might be possible to add this to the current treatment.
Well, I am just curious if others turned up in the panel. In gliomas, these are often just informative and unless something unusual shows up.
DeleteThe trials listed above has some good supportive data. One trails is randomized but open-label, so if the drug of choice isn't received it is possible to withdraw from the trial.
DeleteThere are several trials perusing EGFRvIII as a target, and I still think it is a good target for selected patients. I am not sure why the trial failed. Here are some trials:
https://clinicaltrials.gov/ct2/show/NCT02209376
https://clinicaltrials.gov/ct2/show/NCT02303678
https://clinicaltrials.gov/ct2/show/NCT01967758
https://clinicaltrials.gov/ct2/show/NCT02754362
https://clinicaltrials.gov/ct2/show/NCT02378532
https://clinicaltrials.gov/ct2/show/NCT02432417
There are also some trials for newly diagnosed patients that your wife could be eligible for. I think these are located in the Northeast or Florida.
https://clinicaltrials.gov/ct2/results?term=newly+diagnosed+glioma&recr=Open
https://clinicaltrials.gov/ct2/results?term=glioma+vaccine+newly&recr=Open
On top of these trial options there are a few other options. In Europe, there are clinics that give vaccine treatments to glioma patients. Some are quackish and others legitement.
DeleteHere are the ones I like:
http://www.immune-therapy.net/en/praxisgemeinschaft/aerzte.php
http://www.unifontis.net/en/
There is interesting preclinical data supporting the addition of Chloroquine to standard care. An oncologist might be willing to add this drug since it is so commonly used. It came up a lot for targeting EGFR/EGFRvIII.
I hope all this helps! Let me know if you have questions.
I have the results back for many.
DeleteI have the same question of Rintega.
ReplyDeleteABT-414 is randomized trial. Disappointing if you wanted guaranteed treatment.
This comment has been removed by the author.
ReplyDelete